Ecully, France

Isabelle Chretien


Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 15(Granted Patents)


Location History:

  • Mornant, FR (1997)
  • Ecully, FR (1991 - 1999)

Company Filing History:


Years Active: 1991-1999

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Isabelle Chretien

Introduction

Isabelle Chretien is a prominent inventor based in Ecully, France. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 3 patents to her name, her work has had a substantial impact on medical research and therapeutic applications.

Latest Patents

Isabelle's latest patents include groundbreaking advancements in monoclonal antibodies against human interleukin-4. These patents provide specific antibodies that are crucial for detecting, measuring, and immunopurifying human interleukin-4. Additionally, her work includes methods for blocking the biological activity of this important cytokine, which plays a role in various immune responses.

Career Highlights

Isabelle Chretien is currently associated with Schering Corporation, where she continues to innovate and contribute to the field of immunology. Her expertise in monoclonal antibodies has positioned her as a key figure in the development of new therapeutic strategies.

Collaborations

Throughout her career, Isabelle has collaborated with notable colleagues, including John S. Abrams and Frank D. Lee. These partnerships have fostered a collaborative environment that enhances the research and development of new medical technologies.

Conclusion

Isabelle Chretien's contributions to the field of biotechnology, particularly through her patents on monoclonal antibodies, highlight her role as an influential inventor. Her work continues to pave the way for advancements in medical research and treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…